United States Senate

WASHINGTON, DC 20510

June 21, 2021

The Honorable Patrick Leahy Chairman Senate Committee on Appropriations The Capitol, Room S-128 Washington, DC 20510

The Honorable Patty Murray Chair Subcommittee on Labor, Health and Human Services, and Education, and Related Agencies Dirksen Senate Office Building, Room 136 Washington, DC 20510 The Honorable Richard Shelby Vice Chairman Senate Committee on Appropriations The Capitol, Room S-146A Washington, DC 20510

The Honorable Roy Blunt
Ranking Member
Subcommittee on Labor, Health and Human
Services, and Education, and
Related Agencies
Dirksen Senate Office Building, Room 156
Washington, DC 20510

Dear Chairman Leahy, Vice Chairman Shelby, Chair Murray, and Ranking Member Blunt:

As you and your colleagues begin to work on the Fiscal Year (FY) 2022 appropriations bills, we respectfully request that you maintain a strong commitment to funding for the National Institutes of Health (NIH) in the Labor-Health and Human Services-Education bill. For the past five years, NIH has been able to advance biomedical innovation and research because of sustained investments. Following a year like no other in our Nation's recent history, we have seen unprecedented advances in biomedical science in response to the COVID-19 pandemic, advances that would not have been possible without the groundwork laid over many years of investment in basic research. We commend the Appropriators for continuing to recognize the critical role support for the NIH plays in spurring continued discoveries that will save and improve lives, and lay the foundation for new treatments and therapies that may help the United States address our most challenging public health needs. As researchers around the country confront the impact of the pandemic, including on their work, now, more than ever, it is essential to continue this federal support for the benefit of the American people and the importance of ensuring that our Nation remains at the forefront of medical research.

The NIH is our country's premier institution for biomedical innovation, supporting research in all fifty states. It offers our best hope for treating or curing debilitating diseases, such as heart disease, cancer, diabetes and so many other illnesses that American families battle every day. It is through NIH-supported innovative medical research that we will learn more about emerging conditions resulting from the pandemic, and conduct early stage research to rapidly identify solutions to this and future public health challenges. Demographic changes and the escalating expenses associated with chronic medical conditions cost the federal government and private sector hundreds of billions of dollars each year, but NIH research has laid the groundwork to help curb those trends.

Our investment in the NIH has supported biomedical research in times of triumph, such as when NIH-led researchers decoded the human genome, and in times of trial, such as the current COVID-19 pandemic. The results of this research contribute to improved health outcomes and economic growth. NIH grants fund basic, clinical and translational research that turns bench-side findings into bedside interventions for patients. NIH supports the work of over 300,000 individuals focused on cutting-edge biomedical research at 2,500 institutions across the country. Unfortunately, America has struggled to maintain its position as the world leader in research and development, and researchers have similarly struggled to secure funding. As NIH grants become more competitive, researchers can easily spend half their careers working before receiving a grant. Secure NIH funding allows scientists to do what they do best—discover tomorrow's therapies and cures. It also prevents promising, talented young researchers from leaving the field of biomedical research and ensures that seasoned investigators continue to conduct their research in the United States. We hope that a sustained commitment to NIH funding will help reverse these troubling trends.

We all recognize the difficult choices that need to be made with respect to the budget as we seek to address the ongoing economic crisis caused by the COVID-19 pandemic. If we are to continue grappling with emerging threats, as well as improve the health of Americans and the quality of their lives, we must continue to invest in biomedical research that has the potential to save money, improve lives and offer an economic return for our Nation. As your Committee makes funding decisions for FY 2022, we urge you to consider the tremendous benefits of sustained investment in the NIH and ask you to remember our Nation's role as a world leader in biomedical research and the impact this research has on the American people. We also ask that you include the full allocation of funding for the NIH provided by the 21st Century Cures Act. Investing in research today will continue to yield cures and therapies for patients tomorrow.

Sincerely,

Robert P. Casey, Jr.

United States Senator

Richard Burr

United States Senator

Edward J. Markey

United States Senator

Angus S. King, Jr. *U* United States Senator

James E. Risch

United States Senator

Cory A. Booker United States Senator

Jacky Rosen

United States Senator

Brian Schatz

United States Senator

Rick Scott

United States Senator

Sherrod Brown

United States Senator

Elizabeth Warren

United States Senator

Richard J. Durbin

United States Senator

Debbie Stabenow

United States Senator

Sheldon Whitehouse

Tim Kaine

United States Senator

M. Michael Rounds United States Senator

Thomas R. Carper

United States Senator

United States Senator

Chris Murphy

United States Senator

Tammy Baldwin

United States Senator

Gary C. Peters

United States Senator

Michael F. Bennet United States Senator

Kyrsten Sinema

United States Senator

Susan M. Collins

Steve Daines

United States Senator

Ron Wyden

United States Senator

Benjamin L. Cardin

United States Senator

Maria Cantwell

United States Senator

Kirsten Gillibrand

United States Senator

Kevin Cramer

United States Senator

Mazie K. Hirono

United States Senator

Jack Reed

United States Senator

Mike Crapo

United States Senator

Robert Menendez

Catherine Cortez Masto United States Senator

Tina Smith

United States Senator

Jeanne Shaheen United States Senator

Mark R. Warner United States Senator

Jon Tester United States Senator Deb Fischer

United States Senator

Thom Tillis

United States Senator

Raphael G. Warnock United States Senator

James Lankford United States Senator

John Cornyn

John Hickenlooper United States Senator Roger Marshall, MD United States Senator

Joe Manchin III
United States Senator

James M. Inhofe United States Senator

Tammy Duckworth
United States Senator

Dianne Feinstein United States Senator

Bernard Sanders United States Senator

United States Senator

Roger F. Wicker United States Senator

Ben Ray Lujān United States Senator John Hoeven

United States Senator

Amy Klobuchar United States Senator

Alex Padilla

United States Senator

Richard Blumenthal United States Senator

Dan Sullivan

United States Senator

Chris Van Hollen

United States Senator

Martin Heinrich Christopher A. Coons
United States Senator United States Senator

Todd Ydang

United States Senator

Margaret Wood Hassan United States Senator